European Surgery

, Volume 49, Issue 4, pp 187–191 | Cite as

Hypercalcemia resistant to cinacalcet caused by a mediastinal hyperplastic parathyroid gland in a renal transplant patient

  • Manabu Okada
  • Kenta Futamura
  • Takahisa Hiramitsu
  • Makoto Tsujita
  • Norihiko Goto
  • Shunji Narumi
  • Yoshihiko Watarai
  • Toshihiro Ichimori
  • Yoshihiro Tominaga
case report
First Online:
Received:
Accepted:

Summary

Background

Renal hyperparathyroidism is a common complication in patients with chronic kidney disease. Cinacalcet, a kind of calcimimetic, has been reported to be an effective and safe treatment option in renal transplant patients with hyperparathyroidism. However, some patients require parathyroidectomy due to resistance to cinacalcet treatment. It is uncertain when we should give up treatment with cinacalcet and perform parathyroidectomy for persistent hyperparathyroidism.

Case report

We experience the first documented case in which cinacalcet-resistant hypercalcemia was caused by a mediastinal hyperplastic parathyroid gland after renal transplantation. The patient received total parathyroidectomy with autograft 4 years before renal transplantation. The levels of serum calcium and parathyroid hormone were controlled well with 25 mg daily of cinacalcet. Despite continuous treatment with cinacalcet, the patient developed hypercalcemia, hypercalciuria and nephrocarcinosis after renal transplantation. A mediastinal parathyroid lesion was revealed by imaging. Eventually, parathyroidectomy was performed for the mediastinal gland for the purpose of preventing new stone formation in the renal graft.

Conclusion

It was suggested that prompt parathyroidectomy is preferable rather than prolonged medical treatment for hypercalcemia resistant to cinacalcet caused by persistent hyperparathyroidism after renal transplantation. Furthermore, we should be extremely careful about hypercalcinuria and nephrocalcinosis when we prescribe cinacalcet for patients under hypercalcemia.

Keywords

Chronic kidney disease-mineral and bone disorder Hyperparathyroidism Kidney transplantation Ectopic parathyroid Parathyroidectomy 
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical guidelines

Conflict of interest

M. Okada, K. Futamura, T. Hiramitsu, M. Tsujita, N. Goto, S. Narumi, Y. Watarai, T. Ichimori and Y. Tominaga declare that they have no competing interests.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Dey V, Farrah TE, Traynor JP, Spalding EM, Robertson SE, Geddes CC. Symptomatic fracture risk in the renal replacement therapy population. Nephorol Dial Transplant. 2016. doi: 10.1093/ndt/gfw222. Epub ahead of print.Google Scholar
  2. 2.
    Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109.CrossRefPubMedGoogle Scholar
  3. 3.
    Tassone F, Guarnieri A, Castellano E, Baffoni C, Attanasio R, Borretta G. Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(8):3069–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Copley JB, Wüthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2011;25(1):24–39.CrossRefPubMedGoogle Scholar
  6. 6.
    Pérez-Ricart A, Galicia-Basart M, Alcalde-Rodrigo M, Segarra-Medrano A, Suñé-Negre JM, Montoro-Ronsano JB. Effectiveness of cinacalcet in patients with chronic kidney disease and secondary hyperparathyroidism not receiving dialysis. PLOS ONE. 2016; doi: 10.1371/journal.pone.0161527.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J. 2016;20(3):78–83.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Toro Prieto FJ, Bernal Blanco G, Navarro García M, Cabello Chaves V, Garcíajiménez R, Pereira Palomo P, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc. 2009;41(6):2144–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010;42(7):2503–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Paschoalin RP, Torregrosa JV, Barros X, Durán CE, Campistol JM. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplant Proc. 2012;44(8):2376–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Borchhardt KA, Heinzl H, Mayerwöger E, Hörl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation. 2008;86(7):919–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20(7):1315–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Okada M, Tominaga Y, Izumi K, Nobata H, Yamamoto T, Hiramitsu T, et al. Tertiary hyperparathyroidism resistant to cinacalcet treatment. Ther Apher Dial. 2011;15:33–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Messa P, Regalia A, Alfieri CM, Cresseri D, Forzenigo L, Gandolfo MT, et al. Current indications to parathyroidectomy in CKD patients before and after renal transplantation. J Nephrol. 2013;26(6):1025–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15(3):770–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.CrossRefPubMedGoogle Scholar
  18. 18.
    Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35(6):1226–37.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Narumi S, et al. Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg. 2016;40(3):600–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1(2):323–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006;109(3):339–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36–45.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lee HH, Kim AJ, Ro H, Jung JY, Chang JH, Chung W, et al. Sequential changes of vitamin D level and parathyroid hormone after kidney transplantation. Transplant Proc. 2016;48(3):897–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Rodriguez M, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int. 1991;40(6):1063–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58(2):753–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13(2):551–8.PubMedGoogle Scholar
  30. 30.
    Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, Russmann S, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8(4):803–10.CrossRefPubMedGoogle Scholar
  31. 31.
    Seager CM, Srinivas TR, Flechner SM. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Ann Transplant. 2013;18:31–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Sarfati E, et al. Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. Nephrol Dial Transplant. 2005;20(12):2865.CrossRefPubMedGoogle Scholar
  33. 33.
    Schlosser K, Endres N, Celik I, Fendrich V, Rothmund M, Fernández ED. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J Surg. 2007;31(10):1947–53.CrossRefPubMedGoogle Scholar
  34. 34.
    Hsieh TM, Sun CK, Chen YT, Chou FF. Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am Surg. 2012;78(5):600–6.PubMedGoogle Scholar
  35. 35.
    Park JH, Kang SW, Jeong JJ, Nam KH, Chang HS, Chung WY, et al. Surgical treatment of tertiary hyperparathyroidism after renal transplantation: a 31-year experience in a single institution. Endocr J. 2011;58(10):827–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Tominaga Y, Matsuoka S, Uno N, Tsuzuki T, Hiramitsu T, Goto N, et al. Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients. World J Surg. 2010;34(6):1312–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria 2017

Authors and Affiliations

  • Manabu Okada
    • 1
  • Kenta Futamura
    • 1
  • Takahisa Hiramitsu
    • 1
  • Makoto Tsujita
    • 1
  • Norihiko Goto
    • 1
  • Shunji Narumi
    • 1
  • Yoshihiko Watarai
    • 1
  • Toshihiro Ichimori
    • 1
  • Yoshihiro Tominaga
    • 1
  1. 1.Department of Transplant and Endocrine SurgeryNagoya Daini Red Cross HospitalShowa-kuJapan

Personalised recommendations